Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10933913rdf:typepubmed:Citationlld:pubmed
pubmed-article:10933913lifeskim:mentionsumls-concept:C1412056lld:lifeskim
pubmed-article:10933913lifeskim:mentionsumls-concept:C0001675lld:lifeskim
pubmed-article:10933913lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:10933913lifeskim:mentionsumls-concept:C0085132lld:lifeskim
pubmed-article:10933913lifeskim:mentionsumls-concept:C0599708lld:lifeskim
pubmed-article:10933913lifeskim:mentionsumls-concept:C1947976lld:lifeskim
pubmed-article:10933913lifeskim:mentionsumls-concept:C0598411lld:lifeskim
pubmed-article:10933913lifeskim:mentionsumls-concept:C0598413lld:lifeskim
pubmed-article:10933913lifeskim:mentionsumls-concept:C0750502lld:lifeskim
pubmed-article:10933913lifeskim:mentionsumls-concept:C0443252lld:lifeskim
pubmed-article:10933913lifeskim:mentionsumls-concept:C0442335lld:lifeskim
pubmed-article:10933913pubmed:issue1lld:pubmed
pubmed-article:10933913pubmed:dateCreated2000-9-18lld:pubmed
pubmed-article:10933913pubmed:abstractTextMost lysosomal storage diseases, including mucopolysaccharidosis, affect the central nervous system (CNS). They often induce severe and progressive mental retardation. Replacement therapy by purified enzyme infusions is a promising approach for the treatment of peripheral organs but without effect on CNS pathology because the enzyme cannot cross the blood-brain barrier. Intracranial injection of recombinant adeno-associated virus (AAV) vectors offers an alternative for sustained local enzyme delivery from genetically engineered cells. We stereotactically injected an AAV vector containing the human beta-glucuronidase cDNA into the striatum of adult mice severely affected by mucopolysaccharidosis type VII at the time of treatment. Six weeks later, beta-glucuronidase activity in the injected hemisphere was comparable to that of heterozygous mice, which have a normal phenotype. Areas staining positive for enzyme activity enlarged with time, representing more than 10% of the hemisphere volume by 16 weeks. A complete reversion of lysosomal storage lesions was evident in these areas, as well as in most neurons located in surrounding negative areas and in the noninjected hemisphere. Thus, a single intracerebral injection of AAV vectors could achieve a broad and sustained lysosomal enzyme delivery, allowing for stable reversion of storage lesions in a significant fraction of the adult brain.lld:pubmed
pubmed-article:10933913pubmed:languageenglld:pubmed
pubmed-article:10933913pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10933913pubmed:citationSubsetIMlld:pubmed
pubmed-article:10933913pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10933913pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10933913pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10933913pubmed:statusMEDLINElld:pubmed
pubmed-article:10933913pubmed:monthJanlld:pubmed
pubmed-article:10933913pubmed:issn1525-0016lld:pubmed
pubmed-article:10933913pubmed:authorpubmed-author:BoschAAlld:pubmed
pubmed-article:10933913pubmed:authorpubmed-author:PerretEElld:pubmed
pubmed-article:10933913pubmed:authorpubmed-author:HeardJ MJMlld:pubmed
pubmed-article:10933913pubmed:authorpubmed-author:DesmarisNNlld:pubmed
pubmed-article:10933913pubmed:issnTypePrintlld:pubmed
pubmed-article:10933913pubmed:volume1lld:pubmed
pubmed-article:10933913pubmed:ownerNLMlld:pubmed
pubmed-article:10933913pubmed:authorsCompleteYlld:pubmed
pubmed-article:10933913pubmed:pagination63-70lld:pubmed
pubmed-article:10933913pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10933913pubmed:meshHeadingpubmed-meshheading:10933913...lld:pubmed
pubmed-article:10933913pubmed:meshHeadingpubmed-meshheading:10933913...lld:pubmed
pubmed-article:10933913pubmed:meshHeadingpubmed-meshheading:10933913...lld:pubmed
pubmed-article:10933913pubmed:meshHeadingpubmed-meshheading:10933913...lld:pubmed
pubmed-article:10933913pubmed:meshHeadingpubmed-meshheading:10933913...lld:pubmed
pubmed-article:10933913pubmed:meshHeadingpubmed-meshheading:10933913...lld:pubmed
pubmed-article:10933913pubmed:meshHeadingpubmed-meshheading:10933913...lld:pubmed
pubmed-article:10933913pubmed:meshHeadingpubmed-meshheading:10933913...lld:pubmed
pubmed-article:10933913pubmed:meshHeadingpubmed-meshheading:10933913...lld:pubmed
pubmed-article:10933913pubmed:meshHeadingpubmed-meshheading:10933913...lld:pubmed
pubmed-article:10933913pubmed:meshHeadingpubmed-meshheading:10933913...lld:pubmed
pubmed-article:10933913pubmed:meshHeadingpubmed-meshheading:10933913...lld:pubmed
pubmed-article:10933913pubmed:meshHeadingpubmed-meshheading:10933913...lld:pubmed
pubmed-article:10933913pubmed:meshHeadingpubmed-meshheading:10933913...lld:pubmed
pubmed-article:10933913pubmed:meshHeadingpubmed-meshheading:10933913...lld:pubmed
pubmed-article:10933913pubmed:meshHeadingpubmed-meshheading:10933913...lld:pubmed
pubmed-article:10933913pubmed:year2000lld:pubmed
pubmed-article:10933913pubmed:articleTitleLong-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors.lld:pubmed
pubmed-article:10933913pubmed:affiliationUnité Rétrovirus et Transfert Génétique, CNRS URA 1930, Paris, France.lld:pubmed
pubmed-article:10933913pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10933913pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10933913lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10933913lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10933913lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10933913lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10933913lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10933913lld:pubmed